ProCE Banner Activity

How I Select First-line HBV Therapy in Patients With Abnormal Bone Health

Clinical Thought
Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Dynavax Technologies, Gilead Sciences, and Novartis and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Released: July 23, 2018

Expiration: July 22, 2019

No longer available for credit.

Share

Faculty

Norah Terrault

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead

Faculty Disclosure

Primary Author

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Dynavax Technologies, Gilead Sciences, and Novartis and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.